These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18723840)

  • 21. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perphenazine for schizophrenia.
    Hartung B; Sampson S; Leucht S
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD003443. PubMed ID: 25749632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
    Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
    JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
    Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL; Arvanitis LA; Miller BG
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from each drug trial.
    Marder SR
    Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457
    [No Abstract]   [Full Text] [Related]  

  • 34. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment.
    Czobor P; Volavka J
    Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
    Correll CU; Rummel-Kluge C; Corves C; Kane JM; Leucht S
    Schizophr Bull; 2009 Mar; 35(2):443-57. PubMed ID: 18417466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Problems in evaluating new antipsychotic drugs].
    Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
    Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
    Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.
    Chengappa KN; Goldstein JM; Greenwood M; John V; Levine J
    Clin Ther; 2003 Feb; 25(2):530-41. PubMed ID: 12749512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.
    Gispen-de Wied C; Stoyanova V; Yu Y; Isaac M; Pani L; de Andres-Trelles F
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):804-11. PubMed ID: 22704716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.